STOCK TITAN

BioVaxys Technology Corp - BVAXF STOCK NEWS

Welcome to our dedicated news page for BioVaxys Technology (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BioVaxys Technology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVaxys Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVaxys Technology's position in the market.

Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
acquisition
-
Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
acquisition
-
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
acquisition
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
acquisition
-
Rhea-AI Summary
BioVaxys Technology Corp. completes a non-brokered private placement, raising $501,500 through 16,716,666 Units at $0.03 per Unit. Each Unit includes a Common Share and a Warrant. The Company plans to utilize the proceeds for working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioVaxys Technology Corp. completes the first tranche of a non-brokered private placement, raising $1,103,500 through the issuance of 36,783,334 Units at $0.03 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.05. The Company plans to use the proceeds for working capital, with the second tranche expected to close by February 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
BioVaxys Technology Corp. completes the first tranche of a non-brokered private placement, raising $1,103,500 through the issuance of 36,783,334 Units at $0.03 per Unit. Each Unit includes one Common Share and one Warrant. The Company plans to use the net proceeds for working capital and anticipates closing the second tranche by February 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.11%
Tags
none
-
Rhea-AI Summary
BioVaxys Technology Corp. completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares at a deemed price of $0.03 per common share. The debt did not include accrued salaries to officers or directors, nor payments for Investor Relations Activities. Certain related parties, including BioVaxys CEO James Passin and COO and President Kenneth Kovan, participated in the debt settlement. The securities issued are subject to a four-month hold period from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
-
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has announced the execution of a non-binding Letter of Intent to acquire a core platform technology and entire immunotherapeutics intellectual property portfolio in oncology and other immunological fields. The company has been granted exclusivity while working on the drafting of a definitive agreement with an unnamed biotechnology company's former secured creditor. Investors are advised to use caution in trading the company's shares while discussions are underway, as there is no certainty of reaching a definitive acquisition agreement or completing any transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.53%
Tags
acquisition
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) announced the termination of the US Distribution Agreement for Papilocare and Immunocaps with Procare Health, while the EU clinical development partnership for their ovarian cancer vaccine BVX-0918 remains unchanged. This move allows BioVaxys to refocus on immunotherapeutics, strengthening their balance sheet and advancing initiatives related to immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.53%
Tags
none
BioVaxys Technology Corp

OTC:BVAXF

BVAXF Rankings

BVAXF Stock Data

9.37M
125.30M
6.61%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Etobicoke